Ipamorelin — 10mg
Research-grade Ipamorelin, a selective synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH₂) studied for ghrelin/growth hormone secretagogue receptor binding and pulsatile growth hormone release pathways. 10mg lyophilized powder, 99%+ purity verified by Janoshik Analytical via HPLC and mass spectrometry.
For laboratory research use only.
Not for human or veterinary use.
Not intended for diagnosis, treatment, cure, or prevention of any disease.
Use only in controlled laboratory settings by qualified personnel following appropriate safety procedures.
Ipamorelin (development code NNC-26-0161) was originally developed by Novo Nordisk in the 1990s as the first selective growth hormone secretagogue. It is a synthetic pentapeptide derived from GHRP-1, designed to selectively bind the ghrelin/GHS receptor without significantly affecting cortisol, prolactin, or aldosterone — distinguishing it from earlier GHRPs. Ipamorelin is frequently studied in combination with CJC-1295 (No DAC) for synergistic GHRH/GHS pathway research.
BENEFITS
Selective receptor binding — studied as a clean ghrelin receptor agonist with minimal off-target effects
Pulsatile GH release — investigated for its mimicking of natural growth hormone secretion patterns
Recovery research — explored in tissue repair and recovery models
Stack compatibility — frequently paired with CJC-1295 (No DAC) in GH secretagogue research
Well-characterized — extensive preclinical literature spanning two decades
WHAT RESEARCHERS LOOK AT
Selective GHS receptor (GHSR) agonism without cortisol or prolactin elevation
Pulsatile growth hormone release in pituitary cell cultures
Bone formation models and longitudinal bone growth in rodent studies
Gastric motility and post-operative ileus research (Phase 2 clinical history)
Ghrelin pathway investigation in metabolic and recovery contexts